Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

(NASDAQ:KYTX), EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. Kyverna intends to grant the underwriters a 30-day […]

Freehold Royalties Declares Dividend for December 2025

(TSX:FRU), CALGARY, Alberta, Dec. 15, 2025 (GLOBE NEWSWIRE) — Freehold Royalties Ltd. (Freehold) (TSX: FRU) announces that its Board of Directors has declared a dividend of Cdn. $0.09 per common share to be paid on January 15, 2026 to shareholders of record on December 31, 2025. These dividends are designated as “eligible dividends” for Canadian

EXL Announces Share Repurchase of 1,551,970 Shares

(NASDAQ:EXLS), NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) — EXL [NASDAQ: EXLS], a global data and AI company, announced that on December 15, 2025 it repurchased 1,551,970 shares of the Company's common stock from Orogen Echo LLC (“Orogen”), an affiliate of The Orogen Group LLC, for an aggregate purchase price of $63,373,143, based on a

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

(NASDAQ:GLUE), BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Tuesday, December 16, 2025, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from

ITHAX Acquisition Corp III Announces Closing of $230 Million Initial Public Offering

(NasdaqGM:ITHAU),(NasdaqGM:ITHA),(NasdaqGM:ITHAW), NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) — ITHAX Acquisition Corp III (the “Company”), a newly incorporated blank check company, today announced the closing of its initial public offering of 23,000,000 units at a price of $10.00 per unit, including 3,000,000 units issued pursuant to the full exercise by the underwriter of its over-allotment

FormFactor Expands Silicon Photonics Test Capabilities With Acquisition of Keystone Photonics

FormFactor Expands Silicon Photonics Test Capabilities With Acquisition of Keystone Photonics GlobeNewswire December 15, 2025 LIVERMORE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) — FormFactor, Inc. (NASDAQ: FORM), a leading semiconductor test and measurement supplier, announced today the acquisition of Keystone Photonics, a pioneer in optical probing technology for silicon photonics (SiPh) and co-packaged optics (CPO)

Freehold Royalties Declares Dividend for December 2025

Freehold Royalties Declares Dividend for December 2025 GlobeNewswire December 15, 2025 CALGARY, Alberta, Dec. 15, 2025 (GLOBE NEWSWIRE) — Freehold Royalties Ltd. (Freehold) (TSX: FRU) announces that its Board of Directors has declared a dividend of Cdn. $0.09 per common share to be paid on January 15, 2026 to shareholders of record on December 31,

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results Conference call and webcast to be held at 8 a.m. ET on December 16, 2025 GlobeNewswire December 15, 2025 BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire December 15, 2025 EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that it has commenced an underwritten public offering of $100,000,000 of shares

ITHAX Acquisition Corp III Announces Closing of $230 Million Initial Public Offering

ITHAX Acquisition Corp III Announces Closing of $230 Million Initial Public Offering GlobeNewswire December 15, 2025 NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) — ITHAX Acquisition Corp III (the “Company”), a newly incorporated blank check company, today announced the closing of its initial public offering of 23,000,000 units at a price of $10.00 per unit,

Scroll to Top